Jennifer A. Wargo

85.5k total citations · 22 hit papers
263 papers, 25.5k citations indexed

About

Jennifer A. Wargo is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jennifer A. Wargo has authored 263 papers receiving a total of 25.5k indexed citations (citations by other indexed papers that have themselves been cited), including 188 papers in Oncology, 136 papers in Molecular Biology and 69 papers in Immunology. Recurrent topics in Jennifer A. Wargo's work include Cancer Immunotherapy and Biomarkers (88 papers), Melanoma and MAPK Pathways (69 papers) and Immunotherapy and Immune Responses (53 papers). Jennifer A. Wargo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (88 papers), Melanoma and MAPK Pathways (69 papers) and Immunotherapy and Immune Responses (53 papers). Jennifer A. Wargo collaborates with scholars based in United States, France and Australia. Jennifer A. Wargo's co-authors include Padmanee Sharma, Antoni Ribas, Siwen Hu‐Lieskovan, Beth A. Helmink, Vancheswaran Gopalakrishnan, Keith T. Flaherty, Alexandre Reuben, Alexandria P. Cogdill, Zachary A. Cooper and Dennie T. Frederick and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jennifer A. Wargo

252 papers receiving 25.2k citations

Hit Papers

Primary, Adaptive, and Acquired Resistance to Ca... 2010 2026 2015 2020 2017 2012 2021 2018 2017 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
    2017 3.7k citations Padmanee Sharma, Jennifer A. Wargo et al. profile →
  2. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    2012 1.4k citations Ravid Straussman, Michal Barzily-Rokni et al. Nature profile →
  3. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
    2021 1.1k citations Golnaz Morad, Padmanee Sharma et al. profile →
  4. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
    2018 950 citations Alexandre Reuben, Jennifer A. Wargo et al. profile →
  5. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
    2017 928 citations Alexandria P. Cogdill, Padmanee Sharma et al. profile →
  6. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
    2016 913 citations Jason Roszik, Pei-Ling Chen et al. profile →
  7. The microbiome and human cancer
    2021 834 citations Laurence Zitvogel, Ravid Straussman et al. profile →
  8. The microbiome, cancer, and cancer therapy
    2019 827 citations Jennifer A. Wargo et al. profile →
  9. EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
    2012 767 citations Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery profile →
  10. Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
    2013 610 citations Rizwan Haq, Dennie T. Frederick et al. profile →
  11. Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
    2010 574 citations Andrea Boni, Alexandria P. Cogdill et al. Cancer Research profile →
  12. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
    2017 455 citations Sumit K. Subudhi, Luis M. Vence et al. profile →
  13. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
    2021 401 citations Sarah B. Johnson, Alexandria P. Cogdill et al. profile →
  14. The gut microbiota influences anticancer immunosurveillance and general health
    2018 366 citations Laurence Zitvogel, Jennifer A. Wargo et al. Nature Reviews Clinical Oncology profile →
  15. A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
    2014 357 citations David J. Konieczkowski, Cory M. Johannessen et al. Cancer Discovery profile →
  16. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background
    2012 350 citations Devarati Mitra, Jennifer A. Lo et al. Nature profile →
  17. Targeting the gut and tumor microbiota in cancer
    2022 329 citations Elizabeth M. Park, Guido Kroemer et al. profile →
  18. Modulating the microbiome to improve therapeutic response in cancer
    2019 276 citations Jennifer L. McQuade, Jennifer A. Wargo et al. profile →
  19. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
    2018 266 citations Anu Sharma, Sumit K. Subudhi et al. Clinical Cancer Research profile →
  20. Mechanisms of immune activation and regulation: lessons from melanoma
    2022 149 citations Jennifer A. Wargo et al. profile →
  21. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
    2023 120 citations Joon Seok Park, Francesca S. Gazzaniga et al. Nature profile →
  22. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
    2024 64 citations Tullia C. Bruno, Christian M. Capitini et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer A. Wargo United States 68 15.9k 11.4k 8.2k 3.6k 2.9k 263 25.5k
François Ghiringhelli France 78 13.6k 0.9× 7.6k 0.7× 13.8k 1.7× 3.3k 0.9× 2.5k 0.9× 458 28.1k
Paolo A. Ascierto Italy 75 18.1k 1.1× 11.4k 1.0× 7.1k 0.9× 3.5k 1.0× 2.5k 0.9× 757 25.2k
Alexander M.M. Eggermont Netherlands 72 18.5k 1.2× 9.4k 0.8× 6.7k 0.8× 3.1k 0.9× 2.7k 0.9× 389 25.8k
Richard A. Scolyer Australia 84 21.3k 1.3× 13.3k 1.2× 6.6k 0.8× 3.8k 1.0× 4.3k 1.5× 707 30.6k
John Nemunaitis United States 76 13.9k 0.9× 9.8k 0.9× 6.0k 0.7× 5.0k 1.4× 3.0k 1.1× 547 25.4k
Weiping Zou United States 79 16.9k 1.1× 10.9k 1.0× 19.8k 2.4× 4.1k 1.1× 5.0k 1.8× 188 35.3k
Timothy A. Chan United States 77 10.4k 0.7× 9.4k 0.8× 4.5k 0.6× 5.5k 1.5× 5.2k 1.8× 243 22.7k
Silvia C. Formenti United States 79 15.6k 1.0× 5.1k 0.5× 9.8k 1.2× 6.5k 1.8× 4.5k 1.6× 348 27.2k
Catherine Sautès‐Fridman France 79 14.6k 0.9× 7.8k 0.7× 15.3k 1.9× 5.2k 1.4× 3.7k 1.3× 251 27.8k
Thomas F. Gajewski United States 82 19.8k 1.2× 11.9k 1.0× 20.9k 2.5× 3.1k 0.9× 2.5k 0.9× 321 36.1k

Countries citing papers authored by Jennifer A. Wargo

Since Specialization
Citations

This map shows the geographic impact of Jennifer A. Wargo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer A. Wargo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer A. Wargo more than expected).

Fields of papers citing papers by Jennifer A. Wargo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer A. Wargo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer A. Wargo. The network helps show where Jennifer A. Wargo may publish in the future.

Co-authorship network of co-authors of Jennifer A. Wargo

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer A. Wargo. A scholar is included among the top collaborators of Jennifer A. Wargo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer A. Wargo. Jennifer A. Wargo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stanton, Sasha E., Kristin G. Anderson, Tullia C. Bruno, et al.. (2025). SITC strategic vision: prevention, premalignant immunity, host and environmental factors. Journal for ImmunoTherapy of Cancer. 13(3). e010419–e010419.
2.
Thomas, Andrew Maltez, Marine Fidelle, Bertrand Routy, et al.. (2023). Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nature Reviews Clinical Oncology. 20(9). 583–603. 78 indexed citations
3.
Park, Joon Seok, Francesca S. Gazzaniga, Meng–Huang Wu, et al.. (2023). Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance. Nature. 617(7960). 377–385. 120 indexed citations breakdown →
4.
Witt, Russell G., Yi‐Ju Chiang, Timothy E. Newhook, et al.. (2021). Utilization and evolving prescribing practice of opioid and non‐opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology. 125(4). 719–729. 3 indexed citations
5.
Lucci, Anthony, Carolyn Hall, Sapna P. Patel, et al.. (2020). Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research. 26(8). 1886–1895. 52 indexed citations
6.
Sims, Travis T., Molly B. El Alam, Tatiana V. Karpinets, et al.. (2020). Gut microbiome diversity as an independent predictor of survival in cervical cancer patients receiving chemoradiation.. Journal of Clinical Oncology. 38(15_suppl). 6036–6036. 1 indexed citations
7.
Sharma, Anu, Sumit K. Subudhi, Jorge Blando, et al.. (2018). Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clinical Cancer Research. 25(4). 1233–1238. 266 indexed citations breakdown →
8.
Friedman, Adam A., Yun Xia, Lorenzo Trippa, et al.. (2017). Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clinical Cancer Research. 23(16). 4680–4692. 5 indexed citations
9.
Feldmeyer, Laurence, Courtney W. Hudgens, Priyadharsini Nagarajan, et al.. (2016). Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clinical Cancer Research. 22(22). 5553–5563. 86 indexed citations
10.
Qin, Yong, Jason Roszik, Chandrani Chattopadhyay, et al.. (2016). Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Molecular Cancer Therapeutics. 15(10). 2442–2454. 41 indexed citations
11.
Gopal, Y.N. Vashisht, Helen Rizos, Guo Chen, et al.. (2014). Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma. Cancer Research. 74(23). 7037–7047. 148 indexed citations
12.
Konieczkowski, David J., Cory M. Johannessen, Omar O. Abudayyeh, et al.. (2014). A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery. 4(7). 816–827. 357 indexed citations breakdown →
13.
Smith, Michael P., Berta Sanchez‐Laorden, Kate O’Brien, et al.. (2014). The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα. Cancer Discovery. 4(10). 1214–1229. 171 indexed citations
14.
Cooper, Zachary A., Vikram R. Juneja, Peter T. Sage, et al.. (2014). Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research. 2(7). 643–654. 192 indexed citations
15.
Miao, Benchun, Zhenyu Ji, Li Tan, et al.. (2014). EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery. 5(3). 274–287. 96 indexed citations
16.
Corcoran, Ryan B., S. Michael Rothenberg, Aaron N. Hata, et al.. (2013). TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine. 5(196). 196ra98–196ra98. 110 indexed citations
17.
Maertens, Ophélia, Bryan W. Johnson, Pablo E. Hollstein, et al.. (2012). Elucidating Distinct Roles for NF1 in Melanomagenesis. Cancer Discovery. 3(3). 338–349. 184 indexed citations
18.
Corcoran, Ryan B., Hiromichi Ebi, Alexa B. Turke, et al.. (2012). EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery. 2(3). 227–235. 767 indexed citations breakdown →
19.
Jiang, Xiaofeng, Jun Zhou, Anita Giobbie‐Hurder, Jennifer A. Wargo, & F. Stephen Hodi. (2012). The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. Clinical Cancer Research. 19(3). 598–609. 406 indexed citations
20.
Boni, Andrea, Alexandria P. Cogdill, Ping Dang, et al.. (2010). Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. Cancer Research. 70(13). 5213–5219. 574 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by François Ghiringhelli Breakdown of academic impact, for papers by Paolo A. Ascierto Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by Richard A. Scolyer Breakdown of academic impact, for papers by John Nemunaitis Breakdown of academic impact, for papers by Weiping Zou Breakdown of academic impact, for papers by Timothy A. Chan Breakdown of academic impact, for papers by Silvia C. Formenti Breakdown of academic impact, for papers by Catherine Sautès‐Fridman Breakdown of academic impact, for papers by Thomas F. Gajewski
Rankless by CCL
2026